Related Experiment Video
Updated: Mar 16, 2026

10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.6K
Noncoding RNAs in gastric cancer: Research progress and prospects
1Meng Zhang, Xiang Du, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
World Journal of Gastroenterology
|August 23, 2016
Summary
Noncoding RNAs (ncRNAs) are crucial in gastric cancer (GC) development. This review explores ncRNAs and competing endogenous RNA networks in GC pathobiology and potential therapeutic applications.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Noncoding RNAs (ncRNAs) play vital roles in cellular processes like proliferation and apoptosis.
- Dysregulation of ncRNAs is implicated in the initiation, progression, invasion, and metastasis of various cancers, including gastric cancer (GC).
- Emerging ncRNAs, such as PIWI-interacting RNAs (piRNAs) and circular RNAs (circRNAs), are increasingly recognized for their roles in cancer.
Purpose of the Study:
- To review recent advances in understanding the role of ncRNAs in gastric cancer pathobiology.
- To highlight the significance of competing endogenous RNA (ceRNA) networks in GC tumorigenesis.
- To discuss the potential applications of ncRNAs in GC diagnosis and therapy.
Main Methods:
- Literature review of recent studies on ncRNAs in gastric cancer.
- Analysis of the components and interactions within ceRNA networks relevant to GC.
- Synthesis of current knowledge on ncRNA dysregulation in GC progression.
Main Results:
- ncRNAs are significantly involved in multiple stages of GC development.
- ceRNA networks, comprising mRNAs, microRNAs, lncRNAs, and circRNAs, are critical in GC tumorigenesis.
- Specific ncRNAs show potential as biomarkers and therapeutic targets for GC.
Conclusions:
- ncRNAs are key players in gastric cancer pathobiology.
- Understanding ncRNA-mediated ceRNA networks offers insights into GC mechanisms.
- Targeting ncRNAs presents promising avenues for future GC treatment strategies.
Related Concept Videos
lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs
3.8K
3.8K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
The Nucleolus
10.6K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.6K
Experimental RNAi
8.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.2K
Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K

